Arbutus Biopharma's Upcoming Conferences and Innovations
Arbutus Biopharma's Upcoming Investor Conferences
Arbutus Biopharma Corporation (Nasdaq: ABUS) is on an exciting path as a clinical-stage biopharmaceutical company dedicated to developing treatments for chronic hepatitis B virus (cHBV) infection. With a strong focus on leveraging their extensive virology expertise, the company has announced its participation in two key investor conferences happening soon in New York.
Details of the Conferences
The management team at Arbutus is set to host one-on-one meetings at these important events:
H.C. Wainwright 26th Annual Global Investment Conference
This conference will feature a formal presentation by Arbutus on September 9 at 8:00 am ET. It promises to be a platform where Arbutus will share its innovative approaches and advancements in treatment strategies.
Baird Global Healthcare Conference
The following day, on September 10, Arbutus will engage in a fireside chat at 8:30 am ET, providing further insights into their research and upcoming developments in the field of virology.
How to Access the Presentations
For those interested in following along, live webcasts will be available during these presentations. Additionally, an archived replay will be accessible for a limited period after the events. This ensures that even those unable to attend live can stay informed about Arbutus Biopharma's advancements.
About Arbutus Biopharma Corporation
Arbutus is dedicated to the complex challenge of developing a functional cure for chronic hepatitis B. Their strategic focus includes suppressing HBV DNA, minimizing surface antigen levels, and stimulating HBV-specific immune responses to create a comprehensive treatment approach. The company’s pipeline includes promising compounds such as the RNAi therapeutic imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101, both of which are currently undergoing clinical trials.
Clinical Trial Progress
Imdusiran has already provided compelling clinical data related to its effectiveness in reducing surface antigens and reawakening immune responses to the virus. Currently, it is involved in two Phase 2a combination clinical trials, which highlight the promising trajectory of this therapeutic option. Simultaneously, AB-101 is progressing through a Phase 1a/1b clinical trial, underscoring Arbutus’s commitment to innovation and patient care.
Contact Information for Inquiries
For further information, particularly related to investor relations, individuals can reach out to:
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
Frequently Asked Questions
What is Arbutus Biopharma focused on?
Arbutus Biopharma specializes in developing treatments for chronic hepatitis B virus infections.
When are the upcoming investor conferences?
The conferences are on September 9 and September 10, 2024.
How can I access the conference presentations?
You can access live webcasts during the conferences, which will also be archived afterward.
What treatments are currently in Arbutus's pipeline?
Arbutus is developing imdusiran (AB-729) and AB-101, both of which are in clinical trials.
How can I contact Arbutus for more information?
Contact Lisa M. Caperelli at 215-206-1822 or via email at lcaperelli@arbutusbio.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Lerner Publishing Group Expands Portfolio with New Acquisition
- Plastic Caps and Closures Market Set to Reach USD 96.28 Billion
- Understanding Nexans S.A. Share Capital and Voting Rights
- SS Innovations' First Mantra Surgical System Sale in Latin America
- Yukon Metals Unveils Promising Gold and Copper Discovery
- Constellation Brands Revises Fiscal 2025 Financial Outlook
- Coloplast A/S Share Trading Insights for Board and Executives
- Semnur Pharmaceuticals and Denali Capital Announce Merger
- DemandScience Achieves a Historic 11th Inc. 5000 Honor
- Bio-Based Coatings Market Growth Driven by Eco-Friendly Demand
- Optical Modulators Market Growth Metrics and Key Drivers
- ChartPath and WoundZoom Partner to Revolutionize Wound Care
- Global Cash Handling Device Market Growth Insights
- Affiliated Network Providers and Aurora Health Join Forces
- AGBA and Triller Finalize Amended Merger Agreement Details
- GeoVax Labs, Inc. Announces Upcoming Investor Events!
- Fortun Advance Reports Rapid Asset Growth and Appoints New VP
- Bango Partners with Disney+ to Expand Subscriber Offerings
- Semnur Pharmaceuticals and Denali Capital to Merge for Growth
- Roper Technologies to Showcase Innovations at GS Conference
- Exploring Stereotaxis Robotic Innovations at HRX Congress
- Kronos Bio to Showcase Research at Key Medical Conferences
- Trio Petroleum Corp Boosts Oil and Gas Reserves Estimates
- Exploring the Expanding DNA and Gene Cloning Market Trends
- Exploring Broadcom's Stock Movements and Price Levels Ahead
Recent Articles
- Cyclacel Pharmaceuticals Pursues Hearing After Delisting Notice
- Johnny Clark Welcomes EFFO: The Ultimate Frying Oil Solution
- AGBA and Triller Finalize Amended Merger Agreement Details
- Mount Logan Capital Inc. Expands Workforce with New Hire
- LAVA Therapeutics Prepares for H.C. Wainwright Conference 2024
- CoinW Launches Innovative Futures Grid and CTA Tools for Traders
- Abeona Therapeutics Engages Investors at Upcoming Conferences
- Axxess and Transcend Strategy Group Collaborate for Growth
- Invert Joins Toronto International Film Festival as Partner
- PyroGenesis Secures $1 Million Contract for Graphite Production
- iBio Leaders Set to Speak at Major Investor Conferences
- TransUnion CEO to Speak at Barclays Global Financial Conference
- Interactive Display Market Projected to Hit $18.51 Billion by 2031
- NANO Nuclear Energy Inc. Class Action Lawsuit Update for Investors
- Seritage Growth Properties Investors Alert: Class Action Lawsuit Update
- US Dollar Response to ISM Survey and Global Economic Factors
- Skyecap Achieves 500% Growth: A New Era for SMEs
- RF-Over-Fiber Market Expected to Reach $1 Billion by 2032
- SKF Welcomes Susanne Larsson as Chief Financial Officer
- NEIRO Commits $100K to Support Shiba Inu Rescue Efforts
- ADVANZ PHARMA's Stance on OCALIVA® Marketing Authorization Revocation
- How Ukraine Achieved Major Wartime Debt Restructuring
- Jefferies Upgrades Azelis and IMCD with Positive Market Outlook
- Quidax Sets Milestone as Nigeria’s First SEC Licensed Exchange
- Valmet Sets Schedule for Financial Reporting in 2025